Australian Pharmaceutical Industries

Australian Pharmaceutical Industries (API)

Stock Code

API

Stock Exchange

ax

Australian Pharmaceutical Industries (API) was formed in 1910 and now it is a leading distributor of pharmaceutical and allied products in Australia having alliances with more than 4000 independent pharmacies. API also focuses on retailing through its wholly owned Priceline retail store brand, a major health and beauty brand in Australia. API is a major franchisor in the pharmacy industry. Through its 150 Priceline Pharmacy stores, API offers the pharmacist franchisees a total retail model. The Company listed on the Australian Stock Exchange on 16 June, 1997.

Pfizer Pharmaceutical Wholesale Business


Pharmaceuticals conglomerate, Pfizer have decided to distribute its products directly to chemists.

Australian Pharmaceutical Industries Dividends

1 September, 2010 - 13:39

Peruse the dividend history for AUSTRALIAN PHARMACEUTICAL INDUSTRIES LIMITED. A taxable payment declared by a company's board of directors and given to its shareholders out of the company's current or retained earnings, usually quarterly. Dividends are usually given as cash (cash dividend), but they can also take the form of stock (stock dividend) or other property. Dividends provide an incentive to own stock in stable companies even if they are not experiencing much growth. Companies are not required to pay dividends.

Australian Pharmaceutical Industries (API) Stock Recommendation


Sigma Pharmaceutical (SIP) is bidding for Australian Pharmaceutical Industries (API), a pharmaceutical wholesaler. Sigma Pharmaceutical have announced a bid of $2.20 per share for Australian Pharmaceutical Industries but the market expects another bid as shares surge in API. Stock analyst, Macquarie Research Equities (MRE) said that "expect further bidding to continue, with the key question remaining how much one would pay." MRE expects to see further bidding to continue and likely to come from Symbion (SYB).

Australian Pharmaceutical Industries (API) Shares Recommendation


Deutsche Bank have rated the Australian Pharmaceutical Industries (API) stock with a Hold recommendation dropping their share price target from $3 to $2. The broker notes that there is nothing good to say about the stock and even the stock price weakness finds no opportunities. Risks in the business include margin pressure, weak PBS funding growth and excess competition.

Australian Pharmaceutical Industries (API) Stock Recommendation


ABN Amro has rated the Australian Pharmaceutical Industries (API) stock as Hold, lowering their share price target from $2.81 to $2.37. Australian Pharmaceutical Industries is listed on the Australian Stock Exchange (ASX) under stock code API. Check your charts!

Syndicate content

Recommended Websites